
华为血压表WATCH D3开预售2988元:腕上血压两条路线只有一条有证
这一周,腕表圈的热闹有点挤。9 月 9 日,苹果在秋季发布会端出 Apple Watch Series 12、Ultra 4 和 SE 3,9 月 11 日开启预购,9 月 18 日正式发售。同一天上午 10:08,华为第三代血压表 WATCH D3 开启国内预售,腕部动态血压记录仪定价 2988 元起。OPPO Watch S2 也在同日公布,卡进千元档主打运动燃脂。
行业数据也在给这波「健康表大战」做注脚:2026 年第二季度全球腕戴设备出货量 4801 万台、同比下滑 4.3%,大盘承压,厂商都在往健康监测里找增量。
先辟掉本周传得最凶的两个说法
第一个:「Apple Watch 现在也能测血压了。」假的。把 Ultra 4 和 Series 12 的规格资料和上手文章挨个对一遍,结论一致:这一代升级集中在健康感测、续航与软件功能,没有新增血压、血糖这类突破性健康监测项目。苹果这次的重心全压在心率上——后台心率最快每 5 秒读取一次,频率最高达到上代的 60 倍;HRV(心率变异性)测量频次最高提升 24 倍;再加一个 0~10 分的「准备指数」,综合训练负荷、生命体征和睡眠。苹果甚至把一份对照研究挂上宣传页,以 Polar H10 心率胸带为参照,点名对比佳明、华为、三星、Oura 等产品,宣称这是「可穿戴设备中最准确的心率感测」。注意用词:是心率,不是血压。那「血压趋势追踪」的说法大概率是把苹果已有的「高血压通知」功能张冠李戴了——它是趋势级风险提示,不输出任何血压数值,性质上属于健康参考、不进诊疗流程。
第二个:「D3 是市面上唯一能测血压的表。」这是渠道话术。8 月就有鱼跃 Watch A1 上市对打华为上代 D2——鱼跃就是你家血压仪上大概率印着的那个牌子,如今把血压计技术做进了手表。低价位段还有赛电这类主打「血压手表」的产品。所以真正的分水岭从来不是「能不能测」,而是有没有证。
腕上血压的两条路线:证不一样,卖的东西就不一样
路线一:气囊示波法。表带里藏窄气囊和微泵,真充气、真加压,和医院袖带是同一个物理原理。华为 WATCH D3 走的就是这条:气囊宽度压到 25.5mm,整机约 40g、比上代轻 9%,表带又减了 7.5g。它手里有两张硬证——国家药监局第二类医疗器械注册证,加上市场监督管理部门颁发的计量器具型式批准证书,海外版还过了欧洲 CE MDR 医疗器械认证。
路线二:光学估算。用 PPG 光电信号加算法「估」出血压趋势,没有气囊,宣传话术通常是「血压趋势参考」。这类产品多数没有医疗器械注册——具体某一款有没有证,下单前自己去药监局官网查注册证编号,一分钟的事。苹果那套健康感测(心率、血氧、HRV)在性质上同样属于「健康参考」,不进诊疗流程。
顺带说一句,有医疗证的这类产品,注册名也不叫智能手表,叫「腕部动态血压记录仪」。
2988 元到底值不值:对三笔账
第一笔:上臂式电子血压计。鱼跃 YE680CR 常卖价 179 元,欧姆龙入门款 U10L 参考价 139 元,医疗器械注册证齐全。便宜、准、够用。血压稳定的人,完全没必要多花两千八。
第二笔:医院 24 小时动态血压监测(ABPM)。白天每 15~30 分钟、夜间每 30~60 分钟自动充气测一次。二甲医院 200~300 元,三甲医院 400~500 元,一般走医保。数据权威、能写进病历,缺点是只能做一天。
第三笔:WATCH D3。它解决的是「能不能长期、反复地看趋势」。新增的「轻扰动态血压研究」模式,每天完成 7 次充气测量,就能拿到日间、夜间、24 小时三个血压均值,夜间还会自动加压。为什么强调全天数据?诊室里量出来偏高、回家正常,叫白大衣高血压;诊室正常、夜里却高,叫隐蔽性高血压——后一种靠单次测量基本抓不到。
背景补一句:《中国心血管健康与疾病报告》显示,我国成人高血压患病率已达 31.6%、患病人数约 2.45 亿——这就是各家都往「血压」上押注的原因。把 2988 元拆开看:这块表「手表硬件」的部分大概值一千出头,多出来的钱买的是那两张证和整套动态血压流程。预售期部分渠道有国补 15%,叠加后约 2540 元。
先别急着冲:D3 的四个物理局限
1. 腕式测量的物理差异不会消失:上臂测肱动脉,业界公认更接近中心血压;腕部受位置和高度影响更大,测量时手要抬到心脏水平,姿势不对读数就飘。
2. 续航:540mAh 电池,常规使用约 6 天;一旦开启动态血压监测,约 1 天——想连续看趋势就得每天充电。
3. 替代不了诊断:手表给的是数据,诊断权在医生手里。
4. 数据不能自己拿来改药:血压药调不调、调多少必须由医生判断。
硬件本身确实是代际升级:表体厚度减到 11.3 毫米,屏幕升级为 1.92 英寸 AMOLED、峰值亮度 3000 尼特,新增曜石黑、羽砂金、摩卡金三个配色。健康功能上,心电采集用手指按住侧边电极约 30 秒可提示房颤、室性早搏风险,另有睡眠呼吸暂停风险筛查、17 项一键微体检,气温骤变或海拔升降时会自动提醒测血压,跌倒检测和紧急呼救也都在。
谁该买,谁该省
这三类人,2988 元花得值:确诊高血压、正在调药、需要长期记录的人;独居老人(跌倒检测 + 紧急呼救 + 心电是兜底安全垫);工作强度大、体检血压偏高、没时间反复跑医院的人。
这两类人,把钱省下:血压正常、只想看心率睡眠运动的,买 D3 属于严重浪费,千元档运动表更合适——同日公布的 OPPO Watch S2 就是典型,8.9mm 厚、34.4g、最长 10 天续航,主打运动燃脂。家里已有上臂式血压计、数据一直稳定的,继续用那台就行,139~179 元的机器没有被淘汰——D3 卖的是「趋势」,不是「更准的单点值」。
苹果用户单独提醒一句:如果你在等 Apple Watch 测血压,S12 和 Ultra 4 会让你失望,这一代的升级重心是高频心率、HRV 与恢复数据,没有血压、血糖传感器。Ultra 4 首发 6499 元起。
本文来源:https://post.m.smzdm.com/p/a03q6qrz
若有版权问题,请来信告知:13951431913#139.com 或在右方提交评论。
Huawei WATCH D3 goes on pre-sale for 2988 yuan: only one of the two wrist blood pressure routes has a certificate
This week, the watch circle is a bit crowded. On September 9, Apple unveiled the Apple Watch Series 12, Ultra 4, and SE 3 at its fall conference, with pre-orders starting on September 11 and official sales on September 18. At the same time, at 10:08 a.m., Huawei's third-generation blood pressure watch, the WATCH D3, began its domestic pre-sale, with the wrist dynamic blood pressure recorder priced starting at 2988 yuan. OPPO Watch S2 was also announced on the same day, targeting the 1000-yuan range and focusing on sports fat loss.
Industry data also sheds light on this "health watch battle": global wrist device shipments for the second quarter of 2026 are 48.01 million units, down 4.3% year-on-year, indicating that the market is under pressure, and manufacturers are looking for growth in health monitoring.
Let's debunk the two most widely spread rumors this week first.
The first: "Apple Watch can now measure blood pressure." False. After reviewing the specifications and hands-on articles for the Ultra 4 and Series 12, the conclusion is consistent: this generation's upgrades focus on health sensing, battery life, and software functions, but do not add breakthrough health monitoring items such as blood pressure or blood sugar. Apple's main focus this time is on heart rate——background heart rate reading frequency is up to once every 5 seconds, 60 times higher than the previous generation; HRV (heart rate variability) measurement frequency is increased by up to 24 times; and a 0–10 "readiness index" is added, which comprehensively considers training load, vital signs, and sleep. Apple even cites a comparative study on its webpage, comparing it to the Polar H10 chest strap and other products, claiming it is the "most accurate heart rate sensor in wearable devices". Note the term used: heart rate, not blood pressure. The claim about "blood pressure trend tracking" is likely a misinterpretation of Apple's existing "high blood pressure notification" feature——it provides trend-level risk alerts but outputs no specific blood pressure values, belonging to the category of health reference rather than diagnostic data.
The second: "D3 is the only watch on the market that can measure blood pressure." This is channel rhetoric. In August, Yuwell launched the Watch A1 to compete with the previous Huawei D2——Yuwell is the brand likely printed on your home blood pressure monitor, now bringing blood pressure meter technology into a watch. In the lower price range, there are also products like the Sportsman, which specifically advertise "blood pressure watches". Therefore, the dividing line has never been "whether it can be measured", but rather "whether it has a certificate".
The two routes for wrist blood pressure: different certificates, different products
Route one: Airbag oscillometry. The strap contains a narrow airbag and a micro pump, which truly inflate and pressurize, using the same physical principle as hospital cuffs. The Huawei WATCH D3 follows this route: the airbag width is compressed to 25.5 mm, the total weight is about 40 g (9% lighter than the previous generation), and the strap is 7.5 g lighter. It holds two hard certificates——the second-class medical device registration certificate from the State Drug Administration and the type approval certificate from the Market Supervision Administration, as well as the European CE MDR medical device certification for the overseas version.
Route two: Optical estimation. This uses PPG photoelectric signals and algorithms to "estimate" blood pressure trends, without an airbag, and is often advertised as "blood pressure trend reference". Most such products do not have a medical device registration certificate. To verify, one must check the registration certificate number in the Drug Administration's database before purchasing. Apple's health sensing suite (heart rate, blood oxygen, HRV) similarly falls under "health reference" and does not enter the diagnostic workflow.
By the way, the registered name for this type of product with medical certification is not a "smart watch", but a "wrist dynamic blood pressure recorder".
Is 2988 yuan worth it? Let's do the math
The first comparison: Upper-arm electronic blood pressure monitors. The Yuwell YE680CR typically sells for 179 yuan, and the Omron entry-level U10L is around 139 yuan, both with complete medical device registrations. They are cheap, accurate, and sufficient. For those with stable blood pressure, there is no need to spend an extra 2000 yuan.
The second comparison: Hospital 24-hour dynamic blood pressure monitoring (ABPM). This involves automatic inflation measurements every 15–30 minutes during the day and every 30–60 minutes at night. The cost is 200–300 yuan at a secondary hospital and 400–500 yuan at a tertiary hospital, and is usually covered by insurance. The data is authoritative and can be used in medical records, but the downside is that it can only be performed for one day.
The third comparison: WATCH D3. The value proposition here is the ability to continuously and repeatedly observe trends. The new "light-disturbance dynamic blood pressure study" mode completes 7 inflation measurements per day, yielding average blood pressures for the day, night, and 24-hour period, with automatic pressurization at night. This is crucial because "white coat hypertension" (high in clinic, normal at home) and "masked hypertension" (normal in clinic, high at night) are common, and the latter is difficult to detect with single measurements.
Background context: According to the China Cardiovascular Health and Disease Report, the prevalence of hypertension in adults is 31.6%, with approximately 245 million sufferers——this explains why companies are investing in blood pressure features. Breaking down the 2988 yuan: the "watch hardware" part is worth about a thousand yuan, and the rest pays for the two certificates and the full dynamic blood pressure protocol. During the pre-sale period, some channels offer a 15% subsidy, reducing the effective price to approximately 2540 yuan.
Before rushing to buy, consider the four physical limitations of the D3
1. Wrist measurement has inherent physical differences: upper-arm cuffs measure the brachial artery, which is considered closer to central blood pressure; wrist measurements are more susceptible to position and height, requiring the hand to be raised to heart level, otherwise the readings will drift.
2. Battery life: With a 540 mAh battery, the device lasts about 6 days in normal use, but only about 1 day when dynamic blood pressure monitoring is activated——requiring daily charging to track trends continuously.
3. It does not replace diagnosis: the watch provides data, but the doctor is the authority on diagnosis.
4. You cannot adjust medication based on this data alone: decisions regarding the dosage or type of blood pressure medication must be made by a physician.
The hardware itself represents a generational upgrade: the thickness is reduced to 11.3 mm, the screen is upgraded to a 1.92-inch AMOLED with a peak brightness of 3000 nits, and there are new color options (obsidian black, sand gold, mocha gold). In terms of health functions, the device can detect atrial fibrillation and ventricular premature beats by holding the electrode for about 30 seconds, performs sleep apnea risk screening, 17 one-click micro exams, and automatically reminds users to measure blood pressure during temperature or altitude changes. It also includes fall detection and emergency calling.
Who should buy it, and who should save the money
Three types of people will find value in the 2988 yuan investment: those with diagnosed hypertension who require long-term drug adjustment; the elderly who live alone (for whom fall detection, emergency calling, and ECG serve as safety nets); and individuals with high work stress or borderline high blood pressure who cannot frequently visit the hospital.
Two types of people should skip it: those with normal blood pressure who only need heart rate and sleep tracking, for whom the D3 is overkill——a thousand-yuan sports watch would be more appropriate; and those who already have a working upper-arm monitor with stable data, since the D3 is a "trend" tracker, not a higher-precision single-point meter.
A specific note for Apple users: If you were waiting for blood pressure measurement in the Apple Watch, the S12 and Ultra 4 will disappoint, as the upgrades focus on high-frequency heart rate, HRV, and recovery metrics, lacking blood pressure or blood sugar sensors. The Ultra 4 starts at 6499 yuan.